Wang Xin
Clinical trials sponsored by Wang Xin, explained in plain language.
-
Triple therapy aims to wipe out rectal cancer before surgery
Disease control Not yet recruitingThis phase II trial tests a new approach for high-risk locally advanced rectal cancer. Participants first receive short-course radiotherapy, followed by a combination of chemotherapy (NALIRIFOX) and immunotherapy (Pucotenlimab) for about 6 months. The goal is to see if this regim…
Phase: PHASE2 • Sponsor: Wang Xin • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Can radiotherapy and poop pills outsmart liver cancer resistance?
Disease control Not yet recruitingThis Phase 2 trial tests whether adding personalized radiotherapy (PULSAR) and fecal microbiota transplants (FMT) to standard targeted-immunotherapy can reverse resistance in advanced liver cancer. About 64 patients whose cancer stopped responding to first-line treatment will be …
Phase: PHASE2 • Sponsor: Wang Xin • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC